Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
35.32
-3.77 (-9.64%)
Feb 19, 2025, 4:00 PM EST - Market closed
HRMY Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for HRMY stock have an average target of 55, with a low estimate of 40 and a high estimate of 75. The average target predicts an increase of 55.72% from the current stock price of 35.32.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for HRMY stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 4 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +112.34% | Jan 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +112.34% | Jan 16, 2025 |
| Needham | Needham | Strong Buy Reiterates $52 | Strong Buy | Reiterates | $52 | +47.23% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $75 | Strong Buy | Initiates | $75 | +112.34% | Dec 17, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $51 → $58 | Buy | Maintains | $51 → $58 | +64.21% | Oct 30, 2024 |
Financial Forecast
Revenue This Year
728.17M
from 582.02M
Increased by 25.11%
Revenue Next Year
867.93M
from 728.17M
Increased by 19.19%
EPS This Year
2.42
from 2.13
Increased by 13.79%
EPS Next Year
3.38
from 2.42
Increased by 39.40%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 753.1M | 934.3M | 1.2B | |||
| Avg | 728.2M | 867.9M | 1.1B | |||
| Low | 697.5M | 804.0M | 922.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 29.4% | 28.3% | 38.1% | |||
| Avg | 25.1% | 19.2% | 23.7% | |||
| Low | 19.8% | 10.4% | 6.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.76 | 4.37 | 5.76 | ||
| Avg | 2.42 | 3.38 | 4.57 | ||
| Low | 2.10 | 1.90 | 3.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.6% | 80.2% | 70.6% | ||
| Avg | 13.8% | 39.4% | 35.2% | ||
| Low | -1.5% | -21.6% | -7.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.